PPT-SLE Update “What’s New In Lupus”

Author : dollysprite | Published Date : 2020-08-28

Donald L Kimpel MD March 28 2015 Sentara Medical Center LFADMV The Many features and flavors of Systemic Lupus 11 ACR criteria ACR SLICC Plaquenil Eye Testing

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "SLE Update “What’s New In Lupus”" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

SLE Update “What’s New In Lupus”: Transcript


Donald L Kimpel MD March 28 2015 Sentara Medical Center LFADMV The Many features and flavors of Systemic Lupus 11 ACR criteria ACR SLICC Plaquenil Eye Testing Diabetes and Lupus. Dr. Shauna O’Sullivan, DO, FACP. Assistant Professor of Medicine, USUHS. March 28, 2015. www.myquincy.net. Disclaimer. Nothing to disclose. The views and opinions expressed herein do not necessarily state or reflect those of the Naval Medical Center Portsmouth, DoD, or the United States . Christina McConnell, PGY-3. Which of the following is NOT one of the diagnostic criteria for lupus?. Biopsy proven lupus nephritis with a positive ANA. Hemolytic anemia. Psychosis. Single joint swelling. . Dr. : Mohamed . Abdelhafez. . . . . Nephrology specialist . . MNGH. Agenda. DEFINITION AND EPIDEMIOLOGY. ETIOLOGY AND PATHOGENESIS. RENAL AND EXTRARENAL MANIFESTATIONS. IMMUNOLOGIC TESTS IN LUPUS NEPHRITIS. T. issue Disease. (What is the relationship between UCTD and SLE?). R. John Looney, MD. Stephen and Elise Rosenfeld Distinguished Professor of Allergy and Clinical Immunology. Looking for Lupus. Copyright © 1972-2004 American College of Rheumatology Slide Collection. All rights reserved.. Presented by Camille Keenan, MS3 . & Matthew Covey, MS3. at Pediatric Neurology Grand Rounds. Friday, October 3, . 2014. Mentor: Ian J. Butler, MD. Chief complaint. Child 1. Full term African American female born with red and scaly butterfly rash. . Ella Obrosky, SRNA, University of Pittsburgh Nurse Anesthesia Program. Introduction to Autoimmune Disease. ADs are a heterogeneous group of diseases characterized loss of self-tolerance. Significant . , Antiphospholipid. . Syndrome and Systemic Lupus Erythematosus). Sandeep . Singh, . MD, Shoaib Junejo, MD, Adriana Abrudescu, MD, FACR. ,. . Isaac Sachmechi, MD, FACE, FACP.. Department of Medicine/Rheumatology/Endocrinology Icahn School Of Medicine at Mount . Donald L . Kimpel. , MD. . March 28, 2015. Sentara Medical Center. LFA-DMV . The Many features and. “flavors” of Systemic Lupus. 11 ACR criteria. ACR ~= SLICC. Plaquenil. Eye Testing. . . Diabetes and Lupus. What causes Lupus? Genes No gene or group of genes has been proven to cause lupus. Lupus does, however, appear in certain families, and when one of two identical twins has lupus, there is an increased Presented by: Olivia Wassef What is Systemic Lupus Erythematosus (SLE)? • An Autoimmune Chronic Inflammatory Disease ▫ Immune System produces proteins called autoantibodies that turns against Autoimmune disease is a group of disorders in which tissue injury is caused by humeral (by auto-antibodies) or cells mediated immune response (by auto reactive T cells) to self antigens.. Normal, the immune system does not attach the self. However, there is a large . DR.WASSAN NORI MOHAMMED . Systemic lupus . erythematosus. (SLE). . chronic autoimmune . ,more common in women BY 10Times than men. the incidence is around 1 in 1000 women.. It may cause disease in any system, but principally it affects the joints (90 per cent), skin (80 per cent), lungs, nervous system, kidneys and heart.. Dr. Konstantinos Tselios, MD, PhD. Assistant Professor. McMaster University. Objectives. To discuss the cumulative data for safety and efficacy from the development program of anifrolumab (MUSE, TULIP-1 and TULIP-2 trials) for non-renal, non-neuropsychiatric SLE. Neurology AsiaMarch 2021 immunosuppressive therapy on an individualized level followed by stable maintenance therapy of appropriate strength and duration. The outcome of SLE-ATM is variable and the re

Download Document

Here is the link to download the presentation.
"SLE Update “What’s New In Lupus”"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.

Related Documents